ANTH Anthera Pharmaceuticals, Inc.

0.56
-0.05  -6.95%
Previous Close 0.60
Open 0.60
Price To book 3.35
Market Cap 23.52M
Shares 41,955,000
Volume 1,438,108
Short Ratio 1.36
Av. Daily Volume 1,892,980

SEC filingsSee all SEC filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536778
  2. 8-K - Current report 17514922
  3. 8-K - Current report 162071022
  4. 8-K - Current report 162036802
  5. 8-K - Current report 162027826

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 primary endpoint not met
Blisibimod
IgA nephropathy
Top-line data released December 27, 2016 - missed primary endpoint. New trial to be initiated 1Q 2017.
Sollpura (liprotamase)
Cystic fibrosis who suffer from exocrine pancreatic insufficiency
Phase 3 trial did not meet endpoints - November 10, 2016.
Blisibimod
Lupus

Latest News

  1. SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Anthera Pharmaceuticals, Inc. (ANTH)
  2. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Anthera Pharmaceuticals, Inc.
  3. ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure
  4. Plug Power, Innocoll Drop into Friday’s 52-Week Low Club
  5. Top Analyst Upgrades and Downgrades: Biogen, Comerica, Deere, NVIDIA, 21st Century Fox and More
  6. Anthera Pharma downgraded by Citigroup and Jefferies
  7. Anthera Pharmaceuticals downgraded at SunTrust, price target slashed to $1 from $6
  8. Anthera, Endologix Fall into Wednesday’s 52-Week Low Club
  9. Anthera (ANTH) Stock Falls on Poor Phase III Sollpura Data
  10. Anthera Pharmaceuticals Inc (ANTH) Looks Good For A Recovery
  11. ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Other Events
  12. Anthera Pharma plunges 66% after missing target in study
  13. Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results - Additional Study Needed
  14. Anthera Announces the Phase 3 SOLUTION Study with Sollpura™ in Cystic Fibrosis Patients with Exocrine Pancreatic Insufficiency Demonstrates Encouraging Results – Additional Study Needed
  15. Are Options Traders Betting on a Big Move in Anthera Pharmaceuticals (ANTH) Stock?
  16. ETFs with exposure to Anthera Pharmaceuticals, Inc. : December 22, 2016
  17. Anthera Pharmaceuticals Announces Continuation of SIMPLICITY Study of Sollpura™ Following Positive DMC Review
  18. Derma Sciences Inc (DSCI): Smart Money Continues to Abandon the Stock
  19. Biotech Movers And Shakers: Cascadian Therapeutics Inc (USA) (CASC) And Anthera Pharmaceuticals Inc (ANTH)
  20. ANTHERA PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E

SEC Filings

  1. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17536778
  2. 8-K - Current report 17514922
  3. 8-K - Current report 162071022
  4. 8-K - Current report 162036802
  5. 8-K - Current report 162027826
  6. 8-K - Current report 161987341
  7. 10-Q - Quarterly report [Sections 13 or 15(d)] 161979272
  8. 8-K - Current report 161975021
  9. S-8 - Securities to be offered to employees in employee benefit plans 161919845
  10. SC 13G - Statement of acquisition of beneficial ownership by individuals 161890064